These companies currently offer dividend yields over 3%. Johnson & Johnson (NYSE:JNJ) is the world's largest and most diverse ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & Johnson JNJ has filed a lawsuit against a U.S. government agency over a ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $158.35 which represents a slight increase of $0.11 or 0.07% from the prior close of $158.24. The stock opened at $157.

Johnson & Johnson MedTech announced that the U.S. Food & Drug Administration has approved the Ottava robotic surgical system ...

A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the ...

Raritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration ...